The Centers for Disease Control and Prevention’s independent vaccine advisers voted to recommend a maternal vaccine that would protect infants from respiratory syncytial virus, commonly known as RSV, multiple news outlets reported Friday, amid a growing number of infant hospitalizations for the illness.
RSV is one of the leading causes of hospitalizations among infants in the U.S., according to the ... [+]
The advisers, who voted 11 to 1 in favor, recommended the vaccine for pregnant people in the 32- to 36-week period of gestation to protect against RSV—the leading cause of hospitalization among infants in the U.S.
The CDC director needs to sign off before the vaccines can be administered, but if that happens, the drug, Abrysvo, will become the first vaccine available to protect newborns against RSV.
Abrysvo, a drug produced by Pfizer, is currently approved for adults 60 and older.
This is a breaking story and will be updated.
FDA Approves First RSV Vaccine For Kids—Given To Pregnant Moms—Here’s What To Know (Forbes)